Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12084430 Tricyclic urea compounds as JAK2 V617F inhibitors

Patent 12084430 was granted and assigned to Incyte on September, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Yanran Ai0

Cooper Taylor0

Eddy W. Yue0

Ke Zhang0

Chunhong He0

Date of Patent

September 10, 2024

0

Patent Application Number

181223230

Date Filed

March 16, 2023

0

Patent Citations

US Patent 7879844 Heterocyclic janus kinase 3 inhibitors

0

US Patent 6951865 Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same

0

US Patent 7429456 Identification of a JAK2 mutation in Polycythemia Vera

0

US Patent 7781199 Identification of a JAK2 mutation involved in Vaquez Polyglobulia

0

US Patent 9321730 Method of making and administering quinoline derivatives as anti-cancer agents

0

US Patent 9493419 Quinoline derivatives as anti-cancer agents

0

US Patent 10065974 Compositions and methods for inhibiting arginase activity

0

US Patent 10155987 Methods of predicting resistance to JAK inhibitor therapy

0

...

Patent Primary Examiner

0

CPC Code

0

0

0

0

Patent abstract

The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12084430 Tricyclic urea compounds as JAK2 V617F inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool